Fudan University was established in 1905 in Shanghai, China, and is one of the top universities in China. On April 27, 2000, Shanghai Medical University (established in 1927) merged with Fudan University, evolving into a renowned research university with diverse academic disciplines. Such disciplines include Philosophy, Economics, Law, Education, Literature, History, Sciences, Engineering, Medical Sciences, Management, and Art. Shanghai Medical College, Fudan University is respected for its rigorous medical curriculum and high research capacity. There are seventeen affiliated hospitals, including Zhongshan Hospital and Huashan Hospital. The College also has nine National Health Commission (NHC) key labs, one of which is KLHTA.
KLHTA is based at School of Public Health, Fudan University. It is China’s first HTA agency, and one of the most active agencies in the field of HTA in China. Its goal is to strengthen the impact of HTA on China’s health system through collaboration with policy- and decision-makers. It aims to provide high quality HTA evidence to inform health policy and clinical decision making, to advance talent training and disciplinary development, and to promote knowledge translation. KLHTA is devoted to scientific research, education and training, consultation, exchanges, and collaboration in the field of HTA. KLHTA’s major areas of research are:
KLHTA is solicited frequently to provide consultation and decision-making advice to many departments of NHC and the Shanghai municipal government. In terms of education and training, KLHTA offers master’s and PhD programs in HTA at Fudan University. In May 2017, KLHTA released an HTA online course in Chinese on China’s best Massive Open Online Course (MOOC) platform.
Internationally, KLHTA is a WHO Collaborating Centre for Health Technology Assessment and is also a member of HTAsiaLink.
The China National Health Development Research Center (CNHDRC) is a health think-tank established by the National Health Commission of People’s Republic of China (NHC) and has made remarkable progress on embedding health technology assessment (HTA) into its health system. The main responsibilities of CNHDRC include:
Numerous HTA projects have been conducted upon the request of national and provincial policy-makers and other health-related stakeholders for guiding their decision making and establishing incentive policies to innovative technology industries:
Facing rising health expenditures amidst growing non-communicable disease burdens, the National Center for Medicine and Health Technology Assessment, which was endorsed by the NHC, launched in 2018 under the CNHDRC. The national HTA agency is responsible for assessing new medicines, informing decisions on what goes on the National Essential Medicines List (EML), and guiding regional policy to ensure that priority-setting is based on value.
Various international organizations, including WHO, World Bank, UNICEF, IDRC in Canada, NICE; NGOs such as the Bill & Melinda Gates Foundation; universities such as Imperial College, University of Toronto, University of Queensland, Australia; and Networks like HTAsialink and ISPOR, have been closely linked and have collaborated with CNHDRC to support quality improvements, care integration, efficiency and effectiveness, and the development of Health Technology Assessment in China.